Germany-based CRO continues expansion in US

By Melissa Fassbender contact

- Last updated on GMT

The Massachusetts Biotechnology Council was founded in 1985. (Image: Getty/GrandviewGraphics)
The Massachusetts Biotechnology Council was founded in 1985. (Image: Getty/GrandviewGraphics)
KCR has joined the Massachusetts Biotechnology Council – a “must” for the CRO as it continues to strengthen its footprint in the US market, says CEO.

The Germany-based contract research organization​ (CRO) moved to a new office in Boston earlier this year, at which time KCR CEO, Mike Jagielski, told us​: “Boston is where money and research meet on the East coast​.”

Jagielski said joining the Massachusetts Biotechnology Council (MassBio) – a not-for-profit organization that represents and provides services to life sciences companies – was a natural step for KCR and a “must​” following the recent move to Boston.

KCR has been present on the US market for a few years​,” he told us. “We have been delivering services in the US for some time, but we were missing an office to focus more pro-actively on growing our US business​.”

The CRO also has operation's hubs in Berlin, Kiev, and Warsaw.

Since our office opening in Boston we are building a strong team to manage full-service delivery in the US and connect us effectively with the European operations for US/Europe projects​,” Jagielski added.

Related news

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers